MAIA Biotechnology Files 8-K on Key Agreements and Equity Sales
Ticker: MAIA · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1878313
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
MAIA Bio filed an 8-K detailing material agreements and equity sales from 9/29.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on September 30, 2025, reporting on several events that occurred on September 29, 2025. These include entering into a material definitive agreement, unregistered sales of equity securities, and other events. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by MAIA Biotechnology, including potential new agreements and the issuance of equity, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- September 29, 2025 (date) — Date of earliest event reported
- September 30, 2025 (date) — Filing date
- 444 West Lake Street, Suite 1700 (address) — Principal executive offices
- Chicago, IL 60606 (address) — Principal executive offices
FAQ
What type of material definitive agreement did MAIA Biotechnology enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
What was the nature of the unregistered sales of equity securities?
The filing reports unregistered sales of equity securities, but the specifics regarding the number of shares, price, or purchasers are not detailed in this excerpt.
What are the "Other Events" reported in the 8-K?
The filing lists "Other Events" as a category of information being reported, but the specific nature of these events is not elaborated upon in this excerpt.
When was the report filed with the SEC?
The report was filed on September 30, 2025.
What is MAIA Biotechnology's principal executive office address?
MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Filing Stats: 1,466 words · 6 min read · ~5 pages · Grade level 12.7 · Accepted 2025-09-30 09:00:49
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
- $1 — a purchase price per Investor Share of $1.30, for an aggregate purchase price of
- $2,228,896 — gregate purchase price of approximately $2,228,896. FGMK Business Holdings, LLC, a greater
- $1 million — gregate purchase price of approximately $1 million. The Investor Warrants are exercisabl
- $1.30 — a purchase price per Director Share of $1.30 for an aggregate purchase price of appr
- $25,000 — gregate purchase price of approximately $25,000. The Director Warrants are exercisable
- $2,253,896 — ements are expected to be approximately $2,253,896, prior to deducting offering expenses p
- $1.87 — uary 24, 2025 with an exercise price of $1.87 per share with holders of such warrants
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex4-1.htm (EX-4.1) — 106KB
- ex4-2.htm (EX-4.2) — 95KB
- ex10-1.htm (EX-10.1) — 391KB
- ex10-2.htm (EX-10.2) — 18KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-016200.txt ( ) — 987KB
- maia-20250929.xsd (EX-101.SCH) — 3KB
- maia-20250929_lab.xml (EX-101.LAB) — 33KB
- maia-20250929_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 30, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4